Florida Senate votes to allow generics
The US state of Florida's Senate has voted by 31 votes to nine in favorof permitting generic substitution for a number of brand-name prescription drugs which are currently exempt from state legislation requiring pharmacists to offer generics unless a doctor specifically orders against it.
The Senate Apppriations Committee had previously backed the legislation, HB69 (Marketletter May 7), and the House of Representatives approved it by a vote of 106 to 12 on April 10. The measure will now go to the state's governor for his signature.
One of the branded drugs for which generic substitution will now be permitted is DuPont's Coumadin (warfarin sodium). Barr Laboratories, which produces a generic version of this product, estimates that the legislation could immediately save Florida residents $15.20 million a year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze